New therapy from naïve cells attacks high-risk viruses in cord blood transplant patients

Researchers have expanded the use of virus-specific cell therapy in cord blood transplant patients to successfully prevent three of the most problematic post-transplant viruses affecting this group of patients that have yet to be addressed clinically -- cytomegalovirus, Epstein-Barr virus, and adenovirus.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1HUEwL6